Issue 6/2013
Content (30 Articles)
Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review
Ou Sha, Junfei Niu, Tzi-Bun Ng, Eric Yu-Pang Cho, Xiaoyuan Fu, Wenqi Jiang
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Carolyn D. Britten
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin
Yutaka Ueda, Takayuki Enomoto, Shinya Matsuzaki, Eiji Kobayashi, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Tateki Tsutsui, Tadashi Kimura
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma
Stephen L. Chan, Chi-Hang Wong, Cecilia P. Y. Lau, Qian Zhou, Connie W. C. Hui, Vivian W. Y. Lui, Brigette B. Y. Ma, Anthony T. C. Chan, Winnie Yeo
Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
Kenjiro Aogi, Yoshiaki Rai, Yoshinori Ito, Norikazu Masuda, Junichiro Watanabe, Jun Horiguchi, Takuto Tokudome, Shigemitsu Takashima
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer
Jin Won Kim, Hyun Jin Cho, Miso Kim, Kyung-Hun Lee, Min A. Kim, Sae-Won Han, Do-Youn Oh, Hyuk-Joon Lee, Seock-Ah Im, Tae-You Kim, Han-Kwang Yang, Woo Ho Kim, Yung-Jue Bang
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Young Hak Kim, Masataka Hirabayashi, Shinji Kosaka, Junichi Nikaidoh, Yasumichi Yamamoto, Masatoshi Shimada, Toshiya Toyazaki, Hiroki Nagai, Yuichi Sakamori, Michiaki Mishima
The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats
Feng You, Jinping Hu, Xue Li, Yan Li
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
Lucía Cortejoso, María I. García, Pilar García-Alfonso, Eva González-Haba, Fernando Escolar, María Sanjurjo, Luis A. López-Fernández
Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors
J. F. Deeken, B. Shimkus, A. Liem, D. Hill, J. Gurtler, E. Berghorn, L. Townes, H. Lu, O. Trifan, S. Zhang
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer
Davendra P. S. Sohal, James M. Metz, Weijing Sun, Bruce J. Giantonio, John P. Plastaras, Gregory Ginsberg, Michael L. Kochman, Ursina R. Teitelbaum, Kathleen Harlacker, Daniel F. Heitjan, Michael D. Feldman, Jeffrey A. Drebin, Peter J. O’Dwyer
Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases
Takaaki Tokito, Takehito Shukuya, Hiroaki Akamatsu, Tetsuhiko Taira, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saïk Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii-Saab, François M. Lokiec, Keyvan Rezaï, Aby Buchbinder
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia
Siobhan Hayes, Paul N. Mudd Jr., Daniele Ouellet, Brendan M. Johnson, Daphne Williams, Ekaterina Gibiansky
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
Masashi Kanai, Yoshihiko Otsuka, Kazunori Otsuka, Maremi Sato, Takafumi Nishimura, Yukiko Mori, Michiya Kawaguchi, Etsuro Hatano, Yuzo Kodama, Shigemi Matsumoto, Yoshiki Murakami, Atsushi Imaizumi, Tsutomu Chiba, Jun Nishihira, Hiroyuki Shibata
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
Elisabeth G. Vichaya, Xin Shelley Wang, Jessica A. Boyette-Davis, Tito R. Mendoza, Zijing He, Sheeba K. Thomas, Nina Shah, Loretta A. Williams, Charles S. Cleeland, Patrick M. Dougherty
Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats
Cuirong Zhao, Yuanyuan Li, Yizhuo Qin, Ruiqi Wang, Gang Li, Changjun Sun, Xianjun Qu, Wenbao Li
Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding
David S. Hydock, Chia-Ying Lien, Brock T. Jensen, Carole M. Schneider, Reid Hayward
Bevacizumab and central nervous system (CNS) hemorrhage
Nathalie Letarte, Linda R. Bressler, John L. Villano
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo
Aluvia M. Escalante, Ryan T. McGrath, Matthew R. Karolak, Robert T. Dorr, Ronald M. Lynch, Terry H. Landowski
Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma
Ya Hua Zhong, Jing Dai, Xiao Yong Wang, Cong Hua Xie, Gang Chen, Lei Zeng, Yun Feng Zhou
Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil
Weidong Jia, Zhiqiang Zhu, Tengyue Zhang, Gaofei Fan, Pingsheng Fan, Yabei Liu, Qiaohong Duan
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
Hyeong Su Kim, Jung Han Kim, Byounghoon Kim, Hyun Chang Choi, Jung Hye Kwon, Dae Ro Choi
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
Daryl Sonnichsen, David J. Dorer, Jorge Cortes, Moshe Talpaz, Michael W. Deininger, Neil P. Shah, Hagop M. Kantarjian, Dale Bixby, Michael J. Mauro, Ian W. Flinn, Jeffrey Litwin, Christopher D. Turner, Frank G. Haluska
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer
Kyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym, Kyun Seop Bae, Yong Sang Hong, Heung-Moon Chang, Jae Lyun Lee, Yoon-Koo Kang, Jung Shin Lee, Jae-Gook Shin, Tae Won Kim
Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study
Molouk Hadjibabaie, Shirinsadat Badri, Sarah Ataei, Amir Hossein Moslehi, Iman Karimzadeh, Ardeshir Ghavamzadeh
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
Robert Amato, Mika Stepankiw, Patricia Gonzales
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
Antoinette R. Tan, Darlene G. Gibbon, Mark N. Stein, Diana Lindquist, Jeffery W. Edenfield, Julie C. Martin, Charles Gregory, A. Benjamin Suttle, Hiroomi Tada, Jeffrey Botbyl, Joseph J. Stephenson
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Kazunori Uenaka, Risa Sekiguchi, Takeshi Makiuchi, Christopher A. Slapak, Karim A. Benhadji, Tomohide Tamura
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer
Taishi Hata, Mutsumi Fukunaga, Kohei Murata, Yoshio Uemura, Takayuki Fukuzaki, Hirofumi Ota, Masayuki Ohue, Tadashi Ohnishi, Nobuo Tanaka, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Hirofumi Yamamoto, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori